Latest On Merck & Co., Inc (MRK):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2024-06-17 05:49 EST | Dividend | A dividend of $0.77 has been announced on May 28, 2024. It will be paid Jul 8, 2024 with an ex-dividend date of Jun 17, 2024. | Neutral |  |
| 2024-03-14 05:52 EST | Dividend | A dividend of $0.77 has been announced on Jan 23, 2024. It will be paid Apr 5, 2024 with an ex-dividend date of Mar 14, 2024. | Neutral | |
| 2023-12-14 04:50 EST | Dividend | A dividend of $0.77 has been announced on Nov 28, 2023. It will be paid Jan 8, 2024 with an ex-dividend date of Dec 14, 2023. | Neutral | |
| 2023-09-14 05:50 EST | Dividend | A dividend of $0.73 has been announced on Jul 25, 2023. It will be paid Oct 6, 2023 with an ex-dividend date of Sep 14, 2023. | Neutral | |
| 2023-06-14 05:50 EST | Dividend | A dividend of $0.73 has been announced on May 23, 2023. It will be paid Jul 10, 2023 with an ex-dividend date of Jun 14, 2023. | Neutral | |
About Merck & Co., Inc (MRK):
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as and vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, h read more...ospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
General
- Name Merck & Co., Inc
- Symbol MRK
- Type Common Stock
- Exchange NYSE
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-General
- Full Time Employees 73,000
- Last Split Factor2:1
- Last Split Date1999-02-17
- Fiscal Year EndDecember
- IPO Date1978-01-13
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.merck.com
Valuation
- Trailing PE 27.81
- Forward PE 11.3
- Price/Sales (Trailing 12 Mt.) 3.95
- Price/Book (Most Recent Quarter) 7.46
- Enterprise Value Revenue 4.54
- Enterprise Value EBITDA 16.46
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $6.56
- Next Year EPS Estimate $7.28
- Next Quarter EPS Estimate $1.57
- Profit Margin 15%
- Operating Margin 33%
- Return on Assets 11%
- Return on Equity 28%
- Revenue 47.99 billion
- Earnings Per Share $2.78
- Revenue Per Share $18.97
- Gross Profit 34.57 billion
- Quarterly Earnings Growth 5.5%
ESG Rating
Highlights
- Market Capitalization 195.66 billion
- EBITDA 19.07 billion
- PE Ratio 21.84
- PEG Ratio 1.06
- Analyst Target Price $96.33
- Book Value Per Share $10.01
Share Statistics
- Shares Outstanding 2.53 billion
- Shares Float 2.5 billion
- % Held by Insiders 8%
- % Held by Institutions 75.98%
- Shares Short 20.38 million
- Shares Short Prior Month 18.58 million
- Short Ratio 1.82
- Short % of Float 1%
- Short % of Shares Outstanding 1%
Technicals
- Beta 0.43
- 52 Week High $85.73
- 52 Week Low $63.21
- 50 Day Moving Average 75.09
- 200 Day Moving Average 79.75
Dividends
- Forward Annual Dividend Rate $2.6
- Forward Annual Dividend Yield 3.36%
- Payout Ratio 43%
- Dividend Date 2021-04-07
- ExDividend Date 2021-03-12
- Dividend Per Share $2.44
- Dividend Yield 2.54%
Merck & Co., Inc (MRK) Dividend Calendar:
Merck & Co., Inc pays an annual dividend of $2.6 per share, with a dividend yield of 2.54%.
MRK's last dividend payment was made to shareholders on April 7, 2021.
Merck & Co., Inc pays out 43% of its earnings out as a dividend.
Merck & Co., Inc (MRK) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Merck & Co., Inc (MRK) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Merck & Co., Inc (MRK) Chart:
Merck & Co., Inc (MRK) News:
Below you will find a list of latest news for Merck & Co., Inc (MRK) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Merck & Co., Inc (MRK) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest MRK Trades:
Merck & Co., Inc (MRK) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-05 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-11-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-11-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-11-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-27 | 8-K (Current report) | |
| 2020-10-06 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-13 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-08-06 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-05 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-07-31 | 8-K (Current report) | |
| 2020-07-20 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-24 | 8-K (Current report) | |
Merck & Co., Inc (MRK) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Merck & Co., Inc (MRK). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 8%
Institutional Ownership: 7598%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-10-30 | Michael Nally | EVP, Chief Marketing Officer | Buy | 2,287.00 | 75.89 | 173,560.43 | 13,402.94 | |
| 2020-10-30 | STEVEN MIZELL | EVP, Chief HR Officer | Buy | 4,574.00 | 75.89 | 347,120.86 | 7,624.15 | |
| 2020-10-30 | Frank Clyburn | EVP, Chief Commercial Officer | Buy | 2,287.00 | 75.89 | 173,560.43 | 83,655.80 | |
| 2020-10-05 | Robert M Davis | EVP, Global Svcs & CFO | Sell | 251,273.00 | 81.03 | 20,360,324.54 | 171,055.76 | |
| 2020-10-05 | Robert M Davis | EVP, Global Svcs & CFO | Buy | 251,273.00 | 422,328.76 | | ||
| 2020-08-13 | Sanat Chattopadhyay | Exe V-P & Pres. MMD | Sell | 10,380.00 | 83.01 | 861,675.98 | 67,373.36 | |
| 2020-08-05 | Frank Clyburn | EVP, Chief Commercial Officer | Sell | 18,876.00 | 81.55 | 1,539,273.62 | 80,763.11 | |
| 2020-08-05 | Frank Clyburn | EVP, Chief Commercial Officer | Buy | 18,876.00 | 99,639.11 | | ||
| 2020-07-17 | Julie L. Gerberding | EVP Strat Comm, GI Pub Policy | Sell | 18,174.00 | 80.01 | 1,454,096.29 | 26,577.14 | |
| 2020-07-17 | Julie L. Gerberding | EVP Strat Comm, GI Pub Policy | Sell | 18,111.00 | 80.00 | 1,448,880.00 | 44,751.14 | |
| 2020-07-17 | Julie L. Gerberding | EVP Strat Comm, GI Pub Policy | Buy | 18,111.00 | 62,862.14 | | ||
| 2020-05-07 | WENDELL P WEEKS | Director | Sell | 5,000.00 | 76.02 | 380,103.50 | 100.00 | |
| 2020-05-07 | LESLIE A BRUN | Director | Sell | 5,000.00 | 75.46 | 377,300.00 | 1,948.00 | |
| 2020-05-07 | WENDELL P WEEKS | Director | Buy | 5,000.00 | 5,100.00 | | ||
| 2020-05-07 | LESLIE A BRUN | Director | Buy | 5,000.00 | 6,948.00 | | ||
| 2020-05-05 | Michael Nally | EVP, Chief Marketing Officer | Buy | 2,345.00 | 76.86 | 180,236.70 | 12,053.94 | |
| 2020-05-05 | Rita A Karachun | Sr. VP Fince-Global Controller | Buy | 3,283.00 | 76.86 | 252,331.38 | 29,400.97 | |
| 2020-05-05 | Michael Fleming | SVP Chief Ethics & Com Officer | Buy | 1,290.00 | 76.86 | 99,149.40 | 7,304.33 | |
| 2020-05-05 | Frank Clyburn | EVP, Chief Commercial Officer | Buy | 3,752.00 | 76.86 | 288,378.72 | 82,611.11 | |
| 2020-05-04 | Michael Nally | EVP, Chief Marketing Officer | Buy | 1,298.00 | 77.67 | 100,815.66 | 10,273.94 | |